All In Biotech

Drug Trial Radar · NCT05952856

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,912 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,912

Actual

Start

Aug 10, 2023

Primary completion

Jul 28, 2025

Study completion Jul 28, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with hypercholesterolemia. The primary hypothesis is that enlicitide decanoate is superior to placebo on mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24.

Conditions

  • Hypercholesterolemia
  • Familial Hypercholesterolemia

Interventions

  • Enlicitide DecanoateDrug

    Oral tablet

  • PlaceboDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24Time frame: Baseline and Week 24
  2. Number of Participants With One or More Adverse Events (AEs)Time frame: Up to 60 weeks
  3. Number of Participants Who Discontinued Study Drug Due to an AETime frame: Up to 52 weeks

Locations

168 sites in 14 countries. Site status is shown where the registry gives one.

  • Alliance for Multispecialty Research, LLC ( Site 0093)

    Daphne, Alabama

  • G&L Research ( Site 0043)

    Foley, Alabama

  • Synexus Clinical Research US, Inc.-Synexus Clinical Research US, Inc - Central Phoenix ( Site 0084)

    Phoenix, Arizona

  • National Heart Institute-Research ( Site 0087)

    Beverly Hills, California

  • Clinical Trials Research ( Site 0115)

    Sacramento, California

  • Velocity Clinical Research, Banning ( Site 0017)

    San Bernardino, California

  • Emerson Clinical Research Institute ( Site 0118)

    Washington D.C., District of Columbia

  • Excel Medical Clinical Trials ( Site 0053)

    Boca Raton, Florida

  • Alliance for Multispecialty Research, LLC ( Site 0088)

    Coral Gables, Florida

  • Alliance for Multispecialty Research, LLC ( Site 0094)

    Fort Myers, Florida

  • Velocity Clinical Research, Hallandale Beach ( Site 0018)

    Hallandale, Florida

  • Jacksonville Center for Clinical Research ( Site 0049)

    Jacksonville, Florida

  • South Broward Research ( Site 0051)

    Miramar, Florida

  • Clinical Research Trials of Florida ( Site 0063)

    Tampa, Florida

  • East Coast Institute for Research, LLC ( Site 0033)

    Macon, Georgia

  • Healthcare Research Network - Chicago ( Site 0052)

    Flossmoor, Illinois

  • Synexus Clinical Research US, Inc. ( Site 0109)

    Evansville, Indiana

  • Midwest Institute For Clinical Research ( Site 0059)

    Indianapolis, Indiana

  • Alliance for Multispecialty Research, LLC ( Site 0028)

    Lexington, Kentucky

  • L-MARC Research Center ( Site 0001)

    Louisville, Kentucky

  • Velocity Clinical Research, Covington ( Site 0068)

    Covington, Louisiana

  • Velocity Clinical Research Rockville ( Site 0082)

    Rockville, Maryland

  • Velocity Clinical Research, Gulfport ( Site 0039)

    Gulfport, Mississippi

  • Healthcare Research Network - St. Louis ( Site 0054)

    Hazelwood, Missouri

  • Jubilee Clinical Research ( Site 0106)

    Las Vegas, Nevada

  • AB Clinical Trials ( Site 0070)

    Las Vegas, Nevada

  • New Mexico Clinical Research & Osteoporosis Center ( Site 0005)

    Albuquerque, New Mexico

  • Velocity Clinical Research, Syracuse ( Site 0021)

    East Syracuse, New York

  • Icahn School of Medicine at Mount Sinai-Cardiology ( Site 0002)

    New York, New York

  • Lillestol Research ( Site 0026)

    Fargo, North Dakota

  • altoona center for clinical research ( Site 0089)

    Duncansville, Pennsylvania

  • Cardiology Consultants of Philadelphia Yardley ( Site 0097)

    Yardley, Pennsylvania

  • Piedmont Research Partners ( Site 0090)

    Fort Mill, South Carolina

  • Velocity Clinical Research, Greenville ( Site 0023)

    Greenville, South Carolina

  • Coastal Carolina Research Center ( Site 0006)

    North Charleston, South Carolina

  • Monument Health Clinical Research, a department of Monument -Monument Health Clinical Research, a d ( Site 0009)

    Rapid City, South Dakota

  • Holston Medical Group ( Site 0048)

    Kingsport, Tennessee

  • Alliance for Multispecialty Research, LLC ( Site 0008)

    Knoxville, Tennessee

  • Velocity Clinical Research, Dallas ( Site 0114)

    Dallas, Texas

  • Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0111)

    Houston, Texas

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.